Guardant Health
Logotype for Guardant Health Inc

Guardant Health (GH) investor relations material

Guardant Health Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Guardant Health Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

Portfolio momentum and Guardant360

  • Guardant360 volume growth remained nearly 30%; Guardant Reveal grew over 100% YoY, while Shield volumes reached roughly 3x.

  • Next year, a complete launch of FDA-approved Guardant360 Liquid CDx is expected to support further volume growth.

  • Eleven new Smart Apps launched, including blood-based PD-L1 characterization and immune checkpoint inhibitor prediction; additional launches are planned next year.

  • The Smart Apps platform draws on real-world evidence from hundreds of thousands of patients with EMR, claims and outcomes data.

  • SERENA-6-related breast cancer testing is starting to lift volumes; physician education continues with AstraZeneca and advocacy groups.

Therapy monitoring and tissue testing

  • Nearly 1 million late-stage patients may require therapy selection and repeated response monitoring, representing millions of potential U.S. tests.

  • Guardant360 genomic profiling may be repeated at each cancer progression as tumors evolve and treatment options change.

  • Guardant360 Tissue combines genomics, transcriptomics and methylation, uses less tissue and has low QNS rates; Q2-to-Q3 growth was its largest sequential increase to date.

  • FDA approval for Guardant360 Tissue is targeted for next year; management expects approval and the full Liquid CDx launch to support growth and higher tissue-liquid attachment.

  • Longer term, management expects therapy response monitoring and MRD markets to converge as metastatic drugs move earlier in treatment.

MRD and biopharma data

  • Guardant Reveal and Reveal Ultra are positioned for distinct MRD needs: tissue-free speed and broader tumor detection, and tumor-informed ultra-sensitive testing.

  • Thousands of samples are being run to support clinical-validity studies across major tumor types; data will be presented as it becomes ready.

  • Biopharma work is a fast-growing segment, spanning trial testing, patient monitoring and early treatment-response readouts at 4, 8 and 12 weeks.

  • Data and methylation capabilities may help pharma segment patients for drugs without traditional genomic biomarkers; management sees growth opportunities in coming years.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Guardant Health earnings date

Logotype for Guardant Health Inc
38th Annual Healthcare Conference1 Dec, 2026
Guardant Health
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Guardant Health earnings date

Logotype for Guardant Health Inc
38th Annual Healthcare Conference1 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Guardant Health, Inc. is a cancer-specific diagnostic company that provides blood tests, data sets, and analytics. The company's blood test detects cancer mutations in blood so that clinicians can prescribe medicines to match specific types of cancer. The company also provides its patient data sets and analytic tools to change the way hospitals model cancer outcomes. The company is based in Redwood City, California.